119 In contrast, tumor-specific neoantigens arise from somatic mutations, gene fusions, or aberrant splicing events 120,121 and are absent from normal tissues, making them highly immunogenic
For this article no studies with human participants or animals were performed by any of the authors
Abbreviations AIF: apoptosis-inducing factor ALF: acute liver failure ALT: alanine aminotransferase APACHE II: acute physiology and chronic health evaluation II APAP: acetaminophen AST: aspartate transaminase ATP: adenosine triphosphate DAMP: damage-associated molecular pattern DILI: drug-induced liver injury EndoG: endonuclease G FDA: Food and Drug Administration GDCA: glycodeoxycolic acid GDH: glutamate dehydrogenase GSH: glutathione HMGB1: high mobility group B1 HPLC: high-pressure liquid chromatography INR: international normalized ratio IV: intravenous JNK: c-Jun-N-terminal kinase KCH: Kings College Hospital KIM 1: kidney injury molecule 1 MELD: model for end-stage liver disease miRNA: microRNA mtDNA: mitochondrial DNA NAC: N -acetyl cysteine NAPQI: N -acetyl-para-benzo-quinone imine nDNA: nuclear DNA NK: natural killer NKT: natural killer T cells PO: oral SFN: sulforaphane SOFA: sequential organ failure assessment SULT: sulfotransferase UGT: UDP-glucoronosyl transferase Declarations Conflict of interest None Authors contributions Contributed to the manuscript by drafting the document, formatting the figures and tables, obtaining permission for use of previously published figures, and performing final editing of the content (EY), contributed to the manuscript by writing content and formatting the tables in the manuscript (AB), contributed to the manuscript by drafting sections of the document (MC), contributed to the manuscript by providing editing comments (MK), contributed to the manuscript by providing critical revision and administration during the manuscript writing (NP).
Resveratrol attenuates sepsis-induced cardiomyopathy in rats through anti-ferroptosis via the Sirt1/Nrf2 pathway
(c) Eligibility for a rebate reduction (1) Eligible drug
discussion 1860-1 59
